Brief: Hillstream Advances Next-Gen Multispecific Antibodies For Solid Tumors
20/07/2023 13:34
July 20 (Reuters) - Hillstream BioPharma Inc HILS.O :
* HILLSTREAM ADVANCES NEXT-GEN MULTISPECIFIC ANTIBODIES FOR
SOLID
TUMORS WITH LEAD HER2/HER3 PROGRAM, HSB-3215
* HILLSTREAM BIOPHARMA INC - COMPANY INTENDS TO DEVELOP ITS
LEAD
PROGRAM, HSB-3215 AND FILE AN IND APPLICATION WITH US FDA LATE
NEXT YEAR
Source text for Eikon: ID:nGNXZ73gV
Further company coverage: HILS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing